Johnson & Johnson (J&J) develops products related to human health. It undertakes the research and development, and manufacture and sale of a broad range of pharmaceuticals products and medical devices. The company offers its pharmaceutical prescription products through retailers, wholesalers, hospitals, and health care professionals; and medical devices to physicians, nurses, hospitals, and eye care professionals and clinics.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Through its R&D efforts, the company strives to discover and develop new products, improve existing products, and demonstrate product efficacy and ensure regulatory compliance prior to the launch of the products. It is developing new products and improving existing products to treat cardiovascular diseases, metabolism, immune disorders, infectious and neurological diseases, and cancer. The company owns various patents in different countries for its major revenue generating products such as Stelara, Darzalex (daratumumab), Darzalex Faspro (daratumumab and hyaluronidase-fihj) and others. In FY2023, the company invested US$15,085 million on its R&D activities, which as a percentage of revenue, stood at 17.7%. Operates research facilities in the US, Brazil, China, France, Belgium, Germany, Israel, India, Poland, Singapore, Sweden, the Netherlands, Switzerland, and the UK with R&D support in more than 30 other countries. The company often enters into collaborative agreements, usually with other pharmaceutical or biotechnology firms, aimed at jointly developing and commercializing drug candidates or intellectual property.